There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Differential diagnosis of transplant glomerulopathy, a common lesion observed after
kidney transplant that is associated with poor prognosis, remains challenging because
its morphologic pattern (double contour of the glomerular basement membrane ) is
found in several disease processes. The authors used archetype analysis, a probabilistic
data-driven unsupervised statistical approach, to identify distinct groups of patients
(archetypes) with this condition. By applying this approach to a large, comprehensively
phenotyped multicenter cohort from patients diagnosed with transplant glomerulopathy
on the basis of post-transplant biopsies, the authors identified five archetypes with
distinct clinical, histologic, and immunologic features, as well as different outcomes
(kidney allograft survival rates). The findings suggest that an archetype-based characterization
of this condition may improve risk stratification for individual patients undergoing
kidney transplant and those included in clinical trials. Transplant glomerulopathy,
a common glomerular lesion observed after kidney transplant that is associated with
poor prognosis, is not a specific entity but rather the end stage of overlapping disease
pathways. Its heterogeneity has not been precisely characterized to date. Our study
included consecutive kidney transplant recipients from three centers in France and
one in Canada who presented with a diagnosis of transplant glomerulopathy (Banff cg
score ≥1 by light microscopy), on the basis of biopsies performed from January of
2004 through December of 2014. We used an unsupervised archetype analysis of comprehensive
pathology findings and clinical, immunologic, and outcome data to identify distinct
groups of patients. Among the 8207 post-transplant allograft biopsies performed during
the inclusion period, we identified 552 biopsy samples (from 385 patients) with transplant
glomerulopathy (incidence of 6.7%). The median time from transplant to transplant
glomerulopathy diagnosis was 33.18 months. Kidney allograft survival rates at 3, 5,
7, and 10 years after diagnosis were 69.4%, 57.1%, 43.3%, and 25.5%, respectively.
An unsupervised learning method integrating clinical, functional, immunologic, and
histologic parameters revealed five transplant glomerulopathy archetypes characterized
by distinct functional, immunologic, and histologic features and associated causes
and distinct allograft survival profiles. These archetypes showed significant differences
in allograft outcomes, with allograft survival rates 5 years after diagnosis ranging
from 88% to 22%. Based on those results, we built an online application, which can
be used in clinical practice on the basis of real patients. A probabilistic data-driven
archetype analysis approach applied in a large, well defined multicenter cohort refines
the diagnostic and prognostic features associated with cases of transplant glomerulopathy.
Reducing heterogeneity among such cases can improve disease characterization, enable
patient-specific risk stratification, and open new avenues for archetype-based treatment
strategies and clinical trials optimization.
Despite improvements in outcomes of renal transplantation, kidney allograft loss remains substantial, and is associated with increased morbidity, mortality and costs. Identifying the pathologic pathways responsible for allograft loss, and the attendant development of therapeutic interventions, will be one of the guiding future objectives of transplant medicine. One of the most important advances of the past decade has been the demonstration of the destructive power of anti-HLA alloantibodies and their association with antibody-mediated rejection (ABMR). Compelling evidence exists to show that donor-specific anti-HLA antibodies (DSAs) are largely responsible for the chronic deterioration of allografts, a condition previously attributed to calcineurin inhibitor toxicity and chronic allograft nephropathy. The emergence of sensitive techniques to detect DSAs, together with advances in the assessment of graft pathology, have expanded the spectrum of what constitutes ABMR. Today, subtler forms of rejection--such as indolent ABMR, C4d-negative ABMR, and transplant arteriopathy--are seen in which DSAs exert a marked pathological effect. In addition, arteriosclerosis, previously thought to be a bystander lesion related to the vicissitudes of aging, is accelerated in ABMR. Advances in our understanding of the pathological significance of DSAs and ABMR show their primacy in the mediation of chronic allograft destruction. Therapies aimed at B cells, plasma cells and antibodies will be important therapeutic options to improve the length and quality of kidney allograft survival.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.